AMRI buys two Aptuit facilities
pharmafile | January 13, 2015 | News story | Manufacturing and Production | AMRI, Aptuit, cedarburg, glasgow, oso
Contract research and manufacturing firm AMRI has acquired two businesses from pharmaceutical services company Aptuit in a $60 million deal.
The US company has paid $24 million for Aptuit’s Glasgow aseptic clinical manufacturing site entered into a definitive agreement to pay another $36 million for its Indiana, US-based solid-state chemistry business.
“We are very pleased to acquire these two facilities from Aptuit, which will further AMRI’s expertise in drug product development and aseptic manufacturing services, two areas of our business where we are seeing the fastest level of growth,” says William Marth, AMRI’s president and chief executive.
He adds that the Indiana team will “expand our capabilities in analytical testing to include peptides, proteins and oligonucleotides” and that the Glasgow business “strengthens our front end formulation expertise in our sterile injectable business”.
Marth continues: “In addition, having a Glasgow base of operations provides us with an expanded footprint and customer base in Europe for our parenteral offerings, furthering one of our strategic goals.”
The company also invested in an injectable drug business last year when it bought Oso Biopharmaceuticals Manufacturing for $110 million. This followed a $41 million deal to acquire contract manufacturer Cedarburg Pharmaceuticals, beginning the company’s recent drive to increase its manufacturing capabilities.
Aptuit calls the divested sites ‘non-core’ and says that it will reinvest the money from the transaction into its main business of integrated early discovery to mid-phase drug development.
Doctor Jonathan Goldman, Aptuit’s chief executive, says that the deal would allow the company to “further differentiate our existing, unique capabilities and pursue strategic acquisitions”.
He adds: “Our company has expanded by acquisition and organic growth. Future announcements will describe new additions to our capabilities in discovery and non-clinical development, as well as innovative strategic partnerships.”
AMRI says that expects to complete the transaction early in the first quarter of 2015.
George Underwood
Related Content
UK to push earlier diagnosis and better treatment with 5 AI-driven technology centres
The UK’s Business Secretary has announced the introduction of five specialist collaborative centres across the …
Scottish government invests £11m into Glasgow biotechnology centre
The Scottish government is investing £11 million into the Glasgow-based Industrial Biotechnology Innovation Centre (IBioIC), …
AMRI says troubled Burlington plant back on track
It looks like contract research and manufacturing organisation AMRI can put the quality problems at …
